Tokyo, Japan In 1996 was created CareNet, which is appeared as Corporate Investor. The main office of represented Corporate Investor is situated in the Tokyo. The venture was found in Asia in Japan.
The fund is constantly included in less than 2 deals per year. The high activity for fund was in 2019. The usual things for fund are deals in the range of 10 - 50 millions dollars.
We can highlight the next thriving fund investment areas, such as Biotechnology, Life Science. Besides, a startup requires to be at the age of 2-3 years to receive the investment from the fund. Among the various public portfolio startups of the fund, we may underline Modalis Therapeutics For fund there is no match between the country of its foundation and the country of its the most frequent investments - United States.
The typical case for the fund is to invest in rounds with 6 participants. Despite the CareNet, startups are often financed by SMBC Venture Capital, SBI Investment, Mizuho Capital. The meaningful sponsors for the fund in investment in the same round are UTokyo Innovation Platform, SMBC Venture Capital, SBI Investment.
Related Funds
| Fund Name | Location |
| ARK Investment Management | New York, New York, United States |
| Delaware Street Capital | Chicago, Illinois, United States |
| Kaifu Ziben | Beijing, Beijing, China |
| Salem Halifax Partner | North Carolina, United States, Winston Salem |
| Silvertech Ventures | New York, New York, United States |
| Sinai Ventures | California, Los Angeles, United States |
| Tmeng.cn | Beijing, Beijing, China |
| Tran Ventures | California, San Diego, United States |
| Velocity Equity Partners | Boston, Massachusetts, United States |
Notable deals
| Company | Industry | Round Size | Date | Investors | Location |
| $50M | 25 Aug 2020 | Salt Lake City, Utah, United States | |||
Modalis Therapeutics | $25M | 10 Apr 2019 | Chiyoda, Japan | ||
Modalis Therapeutics | $4M | 20 Dec 2017 | Chiyoda, Japan |
1. You post comments at your own choice and risk. You bear the whole responsibility,related to their substance, content and the fact of publication. We shall not bear anyliability in respect of such comments.
2. While commenting, you shall use only actual, truthful and confirmed data. In thesame time you shall not use vulgar, abusive or defamatory language as well as expresshatred or call to violence or cruelty.
3. We do not intend to delete any comments on the website unless within our “noticeand take down” procedure.
4. We can moderate comments at any time.
5. While commenting, you are under the rule of our website’s terms of use and privacypolicy.
6. We retain our right to delete any comment or any other content of the website at ourwill in case we know or suppose such content is illegal or breaches any lawful right.
Review
- No reviews are submitted yet.
Sign up and get access to full fund profile and advanced analysis.
Full teamIndustries heatmapStages heatmapGeorgaphy breakdownCoinvestorsPortfolio analysisPerformance indexesLatest highlights
Unlock all data Latest deals
| Company | Industry | Round Size | Date | Investors | Location |
| $50M | 25 Aug 2020 | Salt Lake City, Utah, United States | |||
Modalis Therapeutics | $25M | 10 Apr 2019 | Chiyoda, Japan | ||
Modalis Therapeutics | $4M | 20 Dec 2017 | Chiyoda, Japan |
